In a landmark move for preventive healthcare, Lord's Mark Industries Limited has secured India's first manufacturing license for its Biomescan Analytics Platform, a Software as a Medical Device (SaMD).

  • Lord's Mark Industries is the first Indian company to receive a SaMD license for Biomescan.
  • The Indian gut health market is projected to reach USD 1.6 billion by 2034.
  • Plan to establish 3,000 Health & Wellness Centres across India within 3 years.
  • Focus on personalized nutrition and early risk assessment for lifestyle disorders.

In a significant milestone for India’s preventive healthcare ecosystem, Lord's Mark Industries Limited has become the first and only company in the country to receive a manufacturing licence for an In Vitro Diagnostic Software (Software as a Medical Device – SaMD) for its Biomescan Analytics Platform. This development arrives as the nation's gut health sector enters a high-growth phase.

The market dynamics are striking: valued at USD 565.51 million in 2025, the Indian gut health market is projected to surge to USD 1,619.56 million by 2034, expanding at a CAGR of 11.07%. This license positions Lord's Mark Industries at the vanguard of an emerging opportunity, bridging the gap between complex microbiome science and mainstream wellness.

Read Also:Mediterranean Diet in an Indian Kitchen: What to Eat, What to Avoid and Why It Matters

Why This Matters

BozokMedia analysis shows that the shift from reactive to proactive healthcare is the most critical trend in modern medicine. With non-communicable diseases (NCDs) placing a massive burden on India's infrastructure, tools like Biomescan allow for early intervention. By identifying microbial imbalances before they manifest as chronic diseases, the platform enables a shift toward biological precision in nutrition.

"Healthcare is moving from reactive treatment to proactive prevention. Biomescan represents a new era where genomics and nutrition converge for personalized wellness."

The human gut houses trillions of microorganisms that dictate immunity, metabolism, and overall health. Research has linked the microbiome to diabetes, obesity, and cardiovascular diseases. Biomescan utilizes whole metagenome sequencing and a validated bioinformatics pipeline to provide diversity scores and functional metabolic assessments.

Beyond general wellness, the company is strategically focusing on fertility issues, aiming to capture a significant share of this specialized sector. To scale this, Lord's Mark Industries plans to launch an app-based service and collaborate with hospitals to build a network of 3,000 centers, ensuring that the right protein formulations and diets reach the end beneficiary.

Feature Conventional Healthcare Biomescan (Preventive)
Approach Symptom-based (Reactive) Risk-based (Proactive)
Nutrition Generic Guidelines Microbiome-specific Personalization
Goal Disease Management Long-term Wellness & Prevention
Did You Know?: The gut is often referred to as the 'second brain' because it contains its own nervous system and produces about 95% of the body's serotonin!

Frequently Asked Questions

Q1: What is the Biomescan Analytics Platform?
It is a licensed diagnostic software that analyzes gut microbiome data to provide personalized nutritional and health recommendations.

Q2: Can Biomescan be used for medical diagnosis?
No, it is licensed as a wellness and health-information tool and is not intended for standalone clinical diagnosis or therapeutic decision-making.